|
Age (≥ 59 vs. < 59 years)
|
1.387 (0.517–3.723)
|
0.516
|
0.532 (0.264–1.071)
|
0.077
|
0.789 (0.322–1.932)
|
0.604
|
0.619 (0.296–1.292)
|
0.201
|
|
Sex (male vs. female)
|
0.694 (0.197–2.443)
|
0.570
|
1.234 (0.603–2.527)
|
0.565
|
0.898 (0.324–2.492)
|
0.837
|
1.286 (0.605–2.735)
|
0.513
|
|
Stage of primary tumor (I vs. II vs. III)
|
1.308 (0.700–2.447)
|
0.400
|
1.173 (0.775–1.775)
|
0.451
|
1.084 (0.643–1.827)
|
0.762
|
1.189 (0.758–1.863)
|
0.451
|
|
Histology (squamous cell carcinoma vs. non-squamous cell carcinoma)
|
0.755 (0.261–2.183)
|
0.604
|
1.125 (0.510–2.482)
|
0.770
|
0.750 (0.270–2.085)
|
0.582
|
1.420 (0.582–3.466)
|
0.441
|
|
Recurrence site (stump vs. regional lymph nodes vs. ipsilateral lung vs. multiple sites)
|
1.292 (0.689–2.423)
|
0.425
|
1.284 (0.767–2.149)
|
0.342
|
1.439 (0.780–2.655)
|
0.245
|
1.433 (0.840–2.445)
|
0.187
|
|
Interval between surgery and recurrence (≥ 10 vs. < 10 months)
|
0.882 (0.328–2.373)
|
0.803
|
0.690 (0.352–1.351)
|
0.279
|
1.054 (0.434–2.559)
|
0.908
|
0.655 (0.320–1.339)
|
0.246
|
|
BED of radiation (≥ 78 vs. < 78 Gy)
|
0.347 (0.119–1.013)
|
0.053
|
0.905 (0.466–1.758)
|
0.769
|
0.288 (0.104–0.795)
|
0.016
|
1.075 (0.531–2.175)
|
0.841
|
|
Concurrent chemotherapy (yes vs. no)
|
1.222 (0.348–4.294)
|
0.754
|
1.114 (0.485–2.555)
|
0.799
|
1.247 (0.412–3.774)
|
0.696
|
1.150 (0.471–2.808)
|
0.758
|
|
EGFR status (wild-type vs. mutation type vs. unknown)
|
0.265 (0.063–1.112)
|
0.069
|
0.509 (0.238–1.088)
|
0.509
|
1.694 (0.465–6.175)
|
0.425
|
0.418 (0.192–0.912)
|
0.028
|
|
Radiation technique (3D-CRT vs. IMRT vs. SBRT)
|
2.562 (0.887–7.395)
|
0.082
|
1.213 (0.554–2.654)
|
0.630
|
2.047 (0.757–5.537)
|
0.158
|
1.130 (0.472–2.701)
|
0.784
|
|
GTV (≥ 28.7 vs. < 28.7 cm3)
|
1.864 (0.637–5.455)
|
0.256
|
1.246 (0.593–2.617)
|
0.561
|
0.543 (0.201–1.470)
|
0.230
|
1.525 (0.682–3.411)
|
0.304
|
